Secondary analysis of EULAST in 492 patients with early-phase schizophrenia: EQ-5D-5L quality of life improved over up to 19 months with no significant difference between long-acting injectable and oral antipsychotics, or between aripiprazole and paliperidone.
Secondary analysisn = 492
Schulze et al. Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)